ClinicalTrials.gg
Active, not recruitingNCT05753501Updated Nov 4, 2026

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

A Phase 1 interventional study of ABBV-101 in Hematologic Cancer, sponsored by AbbVie. Active, not recruiting at 51 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

Updated Nov 4, 2026Eligibility revisedPrimary outcomes revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
135
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 823 studies in Hematologic Neoplasms with a site in United States — 182 open to participants now, 278 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Enrollment
118th of 660
135 · median 40
Started
2023
with 35 others
Phase 1
197 of 823
37 open now
Primary completion
2031-03
later than 244 of 275 live
Registered
702nd of 823
by date

Among the 823 studies in Hematologic Neoplasms with a site in United States, this one is the 118th largest by enrollment of the 660 interventional ones that give a count, is one of 36 that started in 2023, is one of 197 in phase 1, reaches primary completion later than 244 of the 275 other live ones, and was the 702nd registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 424 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

182 of the 823 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

177 more — sign in →

All 182 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 315 Hematologic Neoplasms studies recruiting now, 211 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 823 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult participants in relapsed or refractory (R/R) non-Hodgkin's lymphomas: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large b-cell lymphoma (DLBCL), non-germinal center B cell (GCB) DLBCL, mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), or transformed indolent NHL. Adverse events will be assessed.

ABBV-101 is an investigational drug being developed for the treatment of NHL. This study is a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-101. Approximately 200 adult participants with multiple NHL subtypes will be enrolled in the study in sites world wide.

Participants will receive escalating oral doses of ABBV-101, until the MAD/MTD is determined, as part of the approximately 88 month study duration.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.

03

Conditions studied

  • Hematologic Cancer

Keywords

  • Chronic lymphocytic leukemia (CLL)
  • Small lymphocytic lymphoma (SLL)
  • Chimeric antigen receptor T-cells (CAR-T)
  • Hematopoietic cell transplant (HCT)
  • Relapsed/refractory (R/R) or ineligible Diffuse large B-cell lymphoma (DLBCL)
  • Mantle cell lymphoma (MCL)
  • Follicular lymphoma (FL)
  • Marginal zone lymphoma (MZL)
  • Waldenström macroglobulinemia (WM)
  • Transformed Indolent non-Hodgkin's lymphoma (INHL)
  • Hematologic Cancer
  • ABBV-101
04

Who can participate

The criteria were revised on the registry on Nov 4, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For Dose Escalation only (including backfill): Participants have received at least two prior systemic therapies, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), have requiring treatment, and have a documented diagnosis for one of the following or later B-cell , from one of the following world health organization (WHO)-defined histologies (Swerdlow et al 2016):

    • Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

      1. For Dose Escalation backfill only - Bruton's tyrosine kinase inhibitor (BTKi)/Bruton's tyrosine kinase degrader (BTKd)-naïve CLL/SLL. Participants with a documented diagnosis of CLL/SLL who have received at least one prior systemic therapy that cannot be a BTK inhibitor or degrader, and, with the exception of BTK pathway agents, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), and have measurable disease requiring treatment.
      2. For Dose Escalation backfill only - BTKi/BCL-2i combination regimen-exposed 2L CLL/SLL. Participants with a documented diagnosis of CLL/SLL who have received one prior systemic therapy with a BTKi and BCL-2i combination regimen, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), and have measurable disease requiring treatment.
    • Chimeric antigen receptor T-cells (CAR-T)/hematopoietic cell transplant (HCT) (R/R) or ineligible diffuse large b-cell lymphoma (DLBCL) from the following histologies: DLBCL not otherwise specified (NOS) (germinal center B cell [GCB] and non-GCB DLBCL), T-cell/histiocyte-rich large B-cell lymphoma, primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, anaplastic lymphoma kinase positive (ALK+) large B-cell lymphoma, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, and high-grade B-cell lymphoma NOS.
    • Mantle cell lymphoma (MCL)
    • Follicular lymphoma [FL] (grades 1-3b)
    • Marginal zone lymphoma [MZL] (splenic, extranodal, and nodal)
    • Waldenström macroglobulinemia (WM)
    • Transformed indolent non-Hodgkin's lymphoma (iNHL)
  • Has an (ECOG) Performance Status (PS) of 0, 1, or 2. For EU only: Participant has an ECOG PS of 0 or 1.
  • Participant has a >= 12 weeks.
  • Prior Bruton's tyrosine kinase inhibitor (BTKi) is allowed.
  • Adequate hematologic, renal, and hepatic function per the protocol.

Exclusion criteria

Exclusion Criteria:

  • Previously treated with a Bruton's tyrosine kinase (BTK) degrader, except ABBV-101.
  • Known active central nervous system (CNS) disease, or primary CNS lymphoma. Participants with prior CNS disease that have been effectively treated may be eligible.
  • Uncontrolled active systemic infection requiring systemic treatment that is ongoing or was completed \<= 14 days before the first dose of study drug, or active cytomegalovirus infection.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Dose Escalation: ABBV-101

    Participants with relapsed or refractory (R/R) Non-Hodgkin's lymphoma (NHL) will receive escalating doses of ABBV-101, until the maximum administered dose (MAD)/Maximum tolerated dose (MTD) is determined, as part of the approximately 88 month study duration.

    Drug: ABBV-101

Interventions

  • DrugABBV-101

    Oral:Tablet

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AE)

    AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Approximately 88 Months

  2. Change in Laboratory Parameters

    Number of participants with clinically significant change from baseline in clinical laboratory test results like hematology will be reported.

    Time frame: Up to Approximately 88 Months

  3. Change in Vital Signs

    Number of participants with clinically significant change from baseline in vital signs like systolic and diastolic blood pressure will be reported.

    Time frame: Up to Approximately 88 Months

  4. Change in Electrocardiogram (ECG)

    12-lead resting ECGs will be recorded. Parameters include RR interval, PR interval, QT interval, and QRS duration.

    Time frame: Up to Approximately 88 Months

Secondary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of ABBV-101

    Maximum observed serum concentration of ABBV-101.

    Time frame: Up to Approximately 88 Months

  2. Time to Cmax (Tmax) of ABBV-101

    Time to Cmax of ABBV-101.

    Time frame: Up to Approximately 88 Months

  3. Area Under the Serum Concentration Versus Time Curve (AUC) of ABBV-101

    Area under the serum concentration versus time curve (AUC) of ABBV-101.

    Time frame: Up to Approximately 88 Months

  4. Number of Participants with Response of Partial Response (PR) or Better Response (Overall Response) per Disease-Specific Criteria

    Number of participants with response of PR or better response (overall response) per disease-specific criteria.

    Time frame: Up to Approximately 88 Months

  5. Duration of Response (DOR)

    DOR is defined for participants achieving PR or better as the time from the initial response per Investigator review to disease progression or death of any cause, whichever occurs earlier.

    Time frame: Up to Approximately 88 Months

07

Study locations

51 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Mar 2031, 93 months after the start.

Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's planned 93 months is above that.

Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2023
First posted
Mar 3, 2023
StartActual
Jun 9, 2023
Primary completionEst.
Mar 2031
CompletionEst.
Mar 2031
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added, 8 sites removed
Show 8 added (4 United States, 1 Canada, 1 Israel, 1 Japan, 1 United Kingdom)
  • Rocky Mountain Cancer Centers - Aurora /ID# 252237 · Aurora, United States
  • Northwestern Medicine - Northwestern Memorial Hospital /ID# 249347 · Chicago, United States
  • University of Cincinnati /ID# 249299 · Cincinnati, United States
  • University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 250341 · Philadelphia, United States
  • Centre Hospitalier De L'Universite De Montreal - Hopital Saint-Luc /ID# 253428 · Montreal, Canada
  • Yitzhak Shamir Medical Center /ID# 254566 · Tsrifin, Israel
  • The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 260375 · Koto-ku, Japan
  • UCLH NHS FT - University College Hospital /ID# 260202 · London, United Kingdom
Show 8 removed
  • Rocky Mountain Cancer Centers - Lone Tree /ID# 252237 · Lone Tree, United States
  • Northwestern University Feinberg School of Medicine /ID# 249347 · Chicago, United States
  • UC Health - Cincinnati /ID# 249299 · Cincinnati, United States
  • University of Pennsylvania /ID# 250341 · Philadelphia, United States
  • CHUM Notre-Dame Hospital /ID# 253428 · Montreal, Canada
  • Yitzhak Shamir Medical Center /ID# 254566 · Ẕerifin, Israel
  • The Cancer Institute Hospital Of JFCR /ID# 260375 · Koto-ku, Japan
  • University College London Hospital /ID# 260202 · London, United Kingdom
Nov 4, 2026
Eligibility
3 inclusion criteria edited, 3 removed; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedFor Dose Escalation (Part 1) only (including backfill): Participants have received at least two prior systemic therapies, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), have measurable disease requiring treatment, and have a documented diagnosis for one of the following third line or later B-cell malignancies, from one of the following world health organization (WHO)-defined histologies (Swerdlow et al 2016):
  • EditedFor Dose Escalation (Part 1) backfill only - Bruton's tyrosine kinase inhibitor (BTKi)/Bruton's tyrosine kinase degrader (BTKd)-naïve CLL/SLL. Participants with a documented diagnosis of CLL/SLL who have received at least one prior systemic therapy that cannot be a BTK inhibitor or degrader, and, with the exception of BTK pathway agents, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), and have measurable disease requiring treatment.
  • EditedFor Dose Escalation (Part 1) backfill only - BTKi/BCL-2i combination regimen-exposed 2L CLL/SLL. Participants with a documented diagnosis of CLL/SLL who have received one prior systemic therapy with a BTKi and BCL-2i combination regimen, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), and have measurable disease requiring treatment.
  • RemovedFor Dose Expansion (Part 2a) CLL/SLL only: Participants with a documented diagnosis of CLL/SLL in their first-line or later treatment.
  • RemovedFor Dose Expansion (Part 2a) DLBCL only: Participants have received at least two prior systemic therapies, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), have measurable disease requiring treatment, and have documented diagnosis of CAR-T/HCT R/R or ineligible non-GCB DLBCL who are in their third line or later treatment with histology based on criteria established by the WHO.
  • RemovedFor Dose Exploration of ABBV-101 combination with venetoclax (Part 2b) CLL/SLL only: Participants with a documented diagnosis of CLL/SLL in their first-line or later treatment: In safety lead-in for each dose level, participants must have received at least one prior systemic therapy.
Exclusion criteria
  • EditedPreviously treated with a Bruton's tyrosine kinase (BTK) degrader, except ABBV-101.
Nov 4, 2026
Interventions
Removed Drug: Venetoclax. Arm changed Part 1: Dose Escalation ABBV-101→Dose Escalation: ABBV-101. Arms removed: Part 2A: Dose Expansion ABBV-101 R/R & Treatment-Naive CLL/SLL·Part 2A: Dose Expansion ABBV-101 R/R non-GCB DLBCL·Part 2B: Dose Expansion ABBV-101 + Venetoclax in CLL/SLL
Nov 4, 2026
Primary outcomes
4 time frame changed
What changed in the outcomes
  • Time frameNumber of Participants with Adverse Events (AE)Up to Approximately 100 Months → Up to Approximately 88 Months
  • Time frameChange in Laboratory ParametersUp to Approximately Two Years → Up to Approximately 88 Months
  • Time frameChange in Vital SignsUp to Approximately Two Years → Up to Approximately 88 Months
  • Time frameChange in Electrocardiogram (ECG)Up to Approximately Two Years → Up to Approximately 88 Months
Nov 4, 2026
Secondary outcomes
5 time frame changed, 3 removed
What changed in the outcomes
  • RemovedMaximum Observed Serum Concentration (Cmax) of VenetoclaxTime frame: Up to Approximately One Year
  • RemovedTime to Cmax (Tmax) of VenetoclaxTime frame: Up to Approximately One Year
  • RemovedArea Under the Serum Concentration Versus Time Curve (AUC) of VenetoclaxTime frame: Up to Approximately One Year
  • Time frameMaximum Observed Serum Concentration (Cmax) of ABBV-101Up to Approximately One Year → Up to Approximately 88 Months
  • Time frameTime to Cmax (Tmax) of ABBV-101Up to Approximately One Year → Up to Approximately 88 Months
  • Time frameArea Under the Serum Concentration Versus Time Curve (AUC) of ABBV-101Up to Approximately One Year → Up to Approximately 88 Months
  • Time frameNumber of Participants with Response of Partial Response (PR) or Better Response (Overall Response) per Disease-Specific CriteriaUp to Approximately Two Years → Up to Approximately 88 Months
  • Time frameDuration of Response (DOR)Up to Approximately Two Years → Up to Approximately 88 Months
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    8 sites added, 8 sites removed
    Show 8 added (4 United States, 1 Canada, 1 Israel, 1 Japan, 1 United Kingdom)
    • Rocky Mountain Cancer Centers - Aurora /ID# 252237 · Aurora, United States
    • Northwestern Medicine - Northwestern Memorial Hospital /ID# 249347 · Chicago, United States
    • University of Cincinnati /ID# 249299 · Cincinnati, United States
    • University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 250341 · Philadelphia, United States
    • Centre Hospitalier De L'Universite De Montreal - Hopital Saint-Luc /ID# 253428 · Montreal, Canada
    • Yitzhak Shamir Medical Center /ID# 254566 · Tsrifin, Israel
    • The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 260375 · Koto-ku, Japan
    • UCLH NHS FT - University College Hospital /ID# 260202 · London, United Kingdom
    Show 8 removed
    • Rocky Mountain Cancer Centers - Lone Tree /ID# 252237 · Lone Tree, United States
    • Northwestern University Feinberg School of Medicine /ID# 249347 · Chicago, United States
    • UC Health - Cincinnati /ID# 249299 · Cincinnati, United States
    • University of Pennsylvania /ID# 250341 · Philadelphia, United States
    • CHUM Notre-Dame Hospital /ID# 253428 · Montreal, Canada
    • Yitzhak Shamir Medical Center /ID# 254566 · Ẕerifin, Israel
    • The Cancer Institute Hospital Of JFCR /ID# 260375 · Koto-ku, Japan
    • University College London Hospital /ID# 260202 · London, United Kingdom
    Eligibility 3 inclusion criteria edited, 3 removed; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedFor Dose Escalation (Part 1) only (including backfill): Participants have received at least two prior systemic therapies, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), have measurable disease requiring treatment, and have a documented diagnosis for one of the following third line or later B-cell malignancies, from one of the following world health organization (WHO)-defined histologies (Swerdlow et al 2016):
    • EditedFor Dose Escalation (Part 1) backfill only - Bruton's tyrosine kinase inhibitor (BTKi)/Bruton's tyrosine kinase degrader (BTKd)-naïve CLL/SLL. Participants with a documented diagnosis of CLL/SLL who have received at least one prior systemic therapy that cannot be a BTK inhibitor or degrader, and, with the exception of BTK pathway agents, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), and have measurable disease requiring treatment.
    • EditedFor Dose Escalation (Part 1) backfill only - BTKi/BCL-2i combination regimen-exposed 2L CLL/SLL. Participants with a documented diagnosis of CLL/SLL who have received one prior systemic therapy with a BTKi and BCL-2i combination regimen, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), and have measurable disease requiring treatment.
    • RemovedFor Dose Expansion (Part 2a) CLL/SLL only: Participants with a documented diagnosis of CLL/SLL in their first-line or later treatment.
    • RemovedFor Dose Expansion (Part 2a) DLBCL only: Participants have received at least two prior systemic therapies, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), have measurable disease requiring treatment, and have documented diagnosis of CAR-T/HCT R/R or ineligible non-GCB DLBCL who are in their third line or later treatment with histology based on criteria established by the WHO.
    • RemovedFor Dose Exploration of ABBV-101 combination with venetoclax (Part 2b) CLL/SLL only: Participants with a documented diagnosis of CLL/SLL in their first-line or later treatment: In safety lead-in for each dose level, participants must have received at least one prior systemic therapy.
    Exclusion criteria
    • EditedPreviously treated with a Bruton's tyrosine kinase (BTK) degrader, except ABBV-101.
    Primary outcomes 4 time frame changed
    What changed in the outcomes
    • Time frameNumber of Participants with Adverse Events (AE)Up to Approximately 100 Months → Up to Approximately 88 Months
    • Time frameChange in Laboratory ParametersUp to Approximately Two Years → Up to Approximately 88 Months
    • Time frameChange in Vital SignsUp to Approximately Two Years → Up to Approximately 88 Months
    • Time frameChange in Electrocardiogram (ECG)Up to Approximately Two Years → Up to Approximately 88 Months
    Secondary outcomes 5 time frame changed, 3 removed
    What changed in the outcomes
    • RemovedMaximum Observed Serum Concentration (Cmax) of VenetoclaxTime frame: Up to Approximately One Year
    • RemovedTime to Cmax (Tmax) of VenetoclaxTime frame: Up to Approximately One Year
    • RemovedArea Under the Serum Concentration Versus Time Curve (AUC) of VenetoclaxTime frame: Up to Approximately One Year
    • Time frameMaximum Observed Serum Concentration (Cmax) of ABBV-101Up to Approximately One Year → Up to Approximately 88 Months
    • Time frameTime to Cmax (Tmax) of ABBV-101Up to Approximately One Year → Up to Approximately 88 Months
    • Time frameArea Under the Serum Concentration Versus Time Curve (AUC) of ABBV-101Up to Approximately One Year → Up to Approximately 88 Months
    • Time frameNumber of Participants with Response of Partial Response (PR) or Better Response (Overall Response) per Disease-Specific CriteriaUp to Approximately Two Years → Up to Approximately 88 Months
    • Time frameDuration of Response (DOR)Up to Approximately Two Years → Up to Approximately 88 Months
    Interventions Removed Drug: Venetoclax. Arm changed Part 1: Dose Escalation ABBV-101→Dose Escalation: ABBV-101. Arms removed: Part 2A: Dose Expansion ABBV-101 R/R & Treatment-Naive CLL/SLL·Part 2A: Dose Expansion ABBV-101 R/R non-GCB DLBCL·Part 2B: Dose Expansion ABBV-101 + Venetoclax in CLL/SLL
    + 5 other changes: identifiers, verification date, description, design details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05753501
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 3, 2023
Start date
Jun 9, 2023
Primary completion
Mar 2031 (estimated)
Completion
Mar 2031 (estimated)
Last update
Nov 4, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion